EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Eccentric hypertrophy impairs outcome after TAVR

R Thalmann, V Obermeier, Dominik S Westphal, I Diebold, T Trenkwalder, C Pellegrini, G Buglio, H Seoudy, P Hoppmann, C Bradaric, U Schön, E Holinski-Feder und 8 weitere

Clinical Research in Cardiology · 2025

DOI: 10.1007/s00392-024-02582-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Research in Cardiology, 2025. Verfasst von R Thalmann und 19 weiteren Autor:innen. Beteiligte Einrichtung: Klinik Und Poliklinik Für Innere Medizin I, University Hospital Rechts Der Isar, School of Medicine and Health, Technical University of Munich, Isman…. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis, Hypertrophy, Left Ventricular, Ventricular Remodeling. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Herzstiftung, Deutsches Zentrum für Herz-Kreislaufforschung, Technische Universität München.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Aortic stenosis (AS) induces cardiac remodeling upon chronic left ventricular (LV) pressure overload. Here, we analyzed the clinical outcome of patients undergoing transcatheter aortic valve replacement (TAVR) for symptomatic AS with regard to varying LV hypertrophy patterns. Moreover, we investigated the genetic influence on development of different hypertrophy patterns, measured by polygenic risk scores (PRS).

Methods

1703 patients with severe AS undergoing TAVR were categorized according to LV mass index and relative wall thickness in four subgroups: normal geometry (NG, n = 57), concentric remodeling (CR; n = 388), concentric hypertrophy (CH; n = 993) and eccentric hypertrophy (EH; n = 265). Data was analyzed retrospectively with regard to clinical outcome. In a substudy, 520 patients affected by CH ( n = 237), EH ( n = 139) or CR ( n = 164) were analyzed using two PRS that have been previously associated with hypertrophic and dilated cardiomyopathy.

Results

1 year after TAVR, for EH, in contrast to the remaining groups (NG, CR, CH), a significant difference in all-cause mortality was observable (mortality 17.4% EH, 14.0% NG, 12.4% CR, 14.0% CH, p = 0.001). This difference was observed up to 4 years (mortality 41.9% EH, 26.9% CH, 28.1% CR, 26.4% NG, p = 0.001). Of note, higher percentiles in a PRS for hypertrophic cardiomyopathy were associated with a reduced likelihood of EH in patients with AS ( p = 0.046).

Conclusions

The EH group had a statistically significant poorer 1-year and 5-year outcomes than the other groups. PRS might help predict myocardial reactions in patients with aortic stenosis in future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcatheter Aortic Valve ReplacementAortic Valve StenosisHypertrophy, Left VentricularVentricular RemodelingVentricular Function, LeftHumansMaleFemaleRetrospective StudiesAged, 80 and overAgedTreatment OutcomeFollow-Up StudiesEchocardiographyRisk FactorsSeverity of Illness Index

Stichwörter der Autor:innen

CardiomyopathyHypertrophyOutcomePolygenic risk scoreTAVRTranscatheter aortic valve replacement

Autor:innen und Institutionen

  • Klinik Und Poliklinik Für Innere Medizin I, University Hospital Rechts Der Isar, School of Medicine and Health, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
  • DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany.
  • Klinik Und Poliklinik Für Innere Medizin I, University Hospital Rechts Der Isar, School of Medicine and Health, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany. dominik.westphal@mri.tum.de.
  • DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany. dominik.westphal@mri.tum.de.
  • Institute of Human Genetics, University Hospital Rechts Der Isar, School of Medicine and Health, Technical University of Munich, Munich, Germany. dominik.westphal@mri.tum.de.
  • MGZ Medizinisch Genetisches Zentrum Munich, Munich, Germany.

Förderung

  • Deutsche Herzstiftung
  • Deutsches Zentrum für Herz-Kreislaufforschung
  • Technische Universität München

Zitieren

APA

Thalmann, R., Obermeier, V., Westphal, D. S., Diebold, I., Trenkwalder, T., Pellegrini, C., Buglio, G., Seoudy, H., Hoppmann, P., Bradaric, C., Schön, U., Holinski-Feder, E., Lettmann, N., Ruge, H., Erlebach, M., Fuetterer, C., Laugwitz, K. L., Krane, M., Frank, D., & Kupatt, C. (2025). Eccentric hypertrophy impairs outcome after TAVR. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-024-02582-4

Vancouver

Thalmann R, Obermeier V, Westphal DS, Diebold I, Trenkwalder T, Pellegrini C, et al. Eccentric hypertrophy impairs outcome after TAVR. Clinical Research in Cardiology. 2025. doi:10.1007/s00392-024-02582-4

BibTeX
@article{Thalmann2025,
  author = {Thalmann, R and Obermeier, V and Westphal, Dominik S and Diebold, I and Trenkwalder, T and Pellegrini, C and Buglio, G and Seoudy, H and Hoppmann, P and Bradaric, C and Schön, U and Holinski-Feder, E and Lettmann, N and Ruge, H and Erlebach, M and Fuetterer, C and Laugwitz, K L and Krane, M and Frank, D and Kupatt, C},
  title = {Eccentric hypertrophy impairs outcome after TAVR},
  journal = {Clinical Research in Cardiology},
  year = {2025},
  doi = {10.1007/s00392-024-02582-4}
}
Kostenlos starten →